Literature DB >> 25742869

Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Bradley A Maron1.   

Abstract

Pulmonary arterial hypertension (PAH) is a highly morbid cardiopulmonary disease characterized by plexogenic pulmonary arteriole remodelling. Importantly, PAH severity correlates inversely with cardiac output and directly with pulmonary vascular resistance and right atrial pressure, illustrating the importance of accurately measured hemodynamics to define the clinical profile of patients. Currently available noninvasive technology offers only hemodynamic estimates. In contrast, right heart catheterization is the principle diagnostic procedure in PAH and is required to: (1) definitively exclude alternative pulmonary vascular diseases; and (2) quantify hemodynamics at baseline, after vasoreactivity testing, or in response to therapy to prognosticate outcome and guide therapeutic escalation. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25742869      PMCID: PMC4377110          DOI: 10.1016/j.cjca.2014.09.021

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  34 in total

1.  Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.

Authors:  Adaani E Frost; Harrison W Farber; Robyn J Barst; Dave P Miller; C Gregory Elliott; Michael D McGoon
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

2.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

3.  Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.

Authors:  Benjamin Fox; David Langleben; Andrew M Hirsch; Robert D Schlesinger; Mark J Eisenberg; Dominique Joyal; Fay Blenkhorn; Lyda Lesenko
Journal:  Can J Cardiol       Date:  2012-07-21       Impact factor: 5.223

Review 4.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.

Authors:  Henning Tiede; Natascha Sommer; Katrin Milger; Robert Voswinckel; Dirk Bandorski; Ralph T Schermuly; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Hossein A Ghofrani
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

6.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

7.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

8.  Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients.

Authors:  Bradley A Maron; Gaurav Choudhary; Umar A Khan; Matthew D Jankowich; Hope McChesney; Sarah J Ferrazzani; Sainath Gaddam; Satish Sharma; Alexander R Opotowsky; Deepak L Bhatt; Thomas P Rocco; Jayashri R Aragam
Journal:  Circ Heart Fail       Date:  2013-06-27       Impact factor: 8.790

9.  Echocardiographic parameters in patients with pulmonary arterial hypertension: correlations with right ventricular ejection fraction derived from cardiac magnetic resonance and hemodynamics.

Authors:  Tao Yang; Yu Liang; Yan Zhang; Qing Gu; Guo Chen; Xin-Hai Ni; Xiu-Zhang Lv; Zhi-Hong Liu; Chang-Ming Xiong; Jian-Guo He
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry.

Authors:  Andrew J Swift; Smitha Rajaram; Judith Hurdman; Catherine Hill; Christine Davies; Tom W Sproson; Allison C Morton; Dave Capener; Charlie Elliot; Robin Condliffe; Jim M Wild; David G Kiely
Journal:  JACC Cardiovasc Imaging       Date:  2013-06-13
View more
  3 in total

1.  Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy.

Authors:  Michele Covella; Ethan J Rowin; Nicholas S Hill; Ioana R Preston; Alberto Milan; Alexander R Opotowsky; Barry J Maron; Martin S Maron; Bradley A Maron
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

2.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

3.  Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.

Authors:  Andriy O Samokhin; Steven Hsu; Paul B Yu; Aaron B Waxman; George A Alba; Bradley M Wertheim; C Danielle Hopkins; Frederick Bowman; Richard N Channick; Ivana Nikolic; Mariana Faria-Urbina; Paul M Hassoun; Jane A Leopold; Ryan J Tedford; Corey E Ventetuolo; Peter J Leary; Bradley A Maron
Journal:  J Heart Lung Transplant       Date:  2019-12-31       Impact factor: 10.247

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.